Novartis’ canakinumab failed to improve survival in Phase III trial

ZURICH (Reuters) – Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.

The Phase III CANOPY-2 study was evaluating canakinumab in combination with the chemotherapy agent docetaxel in 237 adults with non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy, the Swiss drugmaker said in a statement.

The canakinumab development program continues with two Phase III non-small cell lung cancer clinical trials ongoing in first-line and adjuvant settings, Novartis said. Findings will be presented at an upcoming medical meeting.

FILE PHOTO: The company’s logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann/File Photo

Canakinumab is a human monoclonal antibody that could enhance anti-tumour immune response and reduce tumour cell proliferation, survival and invasiveness, Novartis said.

Reporting by Silke Koltrowitz; Editing by Riham Alkousaa and Louise Heavens

 

Reuters source:

https://www.reuters.com/article/us-novartis-canakinumab/novartis-canakinumab-failed-to-improve-survival-in-phase-iii-trial-idUSKBN2B10HC